Upgrade to SI Premium - Free Trial

Neurocrine Biosciences (NBIX)

176.65 +2.50 (1.44%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (7/30/26)

Latest Headlines

Neurocrine Biosciences names three senior vice presidents July 23, 2026 4:06 PM - StreetInsider Neurocrine Biosciences Announces Key Leadership Hiring, Promotions July 23, 2026 4:05 PM - PR NewsWire Neurocrine Bio. (NBIX) PT Raised to $193 at Morgan Stanley July 23, 2026 8:43 AM - StreetInsider Neurocrine Biosciences names Samir Siddhanti chief business officer July 21, 2026 4:06 PM - StreetInsider Neurocrine Biosciences Appoints Samir Siddhanti Chief Business Officer July 21, 2026 4:05 PM - PR NewsWire Neurocrine Bio. (NBIX) PT Raised to $200 at Guggenheim July 21, 2026 6:45 AM - StreetInsider Neurocrine Bio. (NBIX) PT Raised to $200 at Wells Fargo July 17, 2026 6:42 AM - StreetInsider Form 4 NEUROCRINE BIOSCIENCES For: Jul 07 Filed by: Delaet Ingrid July 15, 2026 11:53 AM - SEC Filing Form 4 NEUROCRINE BIOSCIENCES For: Jul 10 Filed by: Delaet Ingrid July 13, 2026 4:28 PM - SEC Filing Form 4 NEUROCRINE BIOSCIENCES For: Jul 09 Filed by: Lippoldt Darin July 13, 2026 4:27 PM - SEC Filing Neurocrine Bio. (NBIX) PT Raised to $170 at BMO Capital July 13, 2026 7:34 AM - StreetInsider Neurocrine Bio. (NBIX) PT Raised to $200 at Truist Securities July 13, 2026 7:08 AM - StreetInsider Form 144 NEUROCRINE BIOSCIENCES Filed by: Delaet Ingrid July 10, 2026 4:39 PM - SEC Filing Form 4 NEUROCRINE BIOSCIENCES For: Jul 07 Filed by: Delaet Ingrid July 9, 2026 6:41 PM - SEC Filing Form 144 NEUROCRINE BIOSCIENCES Filed by: Lippoldt Darin July 9, 2026 4:27 PM - SEC Filing Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results July 9, 2026 4:01 PM - PR NewsWire Form 144 NEUROCRINE BIOSCIENCES Filed by: Delaet Ingrid July 7, 2026 4:33 PM - SEC Filing Neurocrine Bio. (NBIX) PT Raised to $195 at RBC Capital July 7, 2026 7:55 AM - StreetInsider Neurocrine starts CAH drug trial in children under age 4 July 1, 2026 4:05 PM - StreetInsider Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia July 1, 2026 4:05 PM - PR NewsWire Form 4 NEUROCRINE BIOSCIENCES For: Jun 26 Filed by: Lippoldt Darin June 30, 2026 4:52 PM - SEC Filing Form 144 NEUROCRINE BIOSCIENCES Filed by: Lippoldt Darin June 29, 2026 4:44 PM - SEC Filing Form 144 NEUROCRINE BIOSCIENCES Filed by: Lippoldt Darin June 26, 2026 4:25 PM - SEC Filing Stifel Reiterates Buy Rating on Neurocrine Bio. (NBIX) June 22, 2026 9:29 AM - StreetInsider Neurocrine Biosciences (NBIX) Presents New VYKAT XR (diazoxide choline) Data June 15, 2026 4:11 PM - StreetInsider Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Foll June 15, 2026 4:10 PM - PR NewsWire Neurocrine Biosciences (NBIX) Presents First Retrospective Case Series of CRENESSITY June 15, 2026 4:06 PM - StreetInsider Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026 June 15, 2026 4:05 PM - PR NewsWire Neurocrine presents two-year CRENESSITY data showing growth improvements June 15, 2026 8:36 AM - StreetInsider Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improved Growth Measures in Pediatric Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2026 June 15, 2026 8:35 AM - PR NewsWire Neurocrine shows two-year CRENESSITY data at ENDO 2026 medical meeting June 15, 2026 8:30 AM - StreetInsider Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026 June 15, 2026 8:30 AM - PR NewsWire Form 4 NEUROCRINE BIOSCIENCES For: Jun 05 Filed by: SHERWIN STEPHEN A June 9, 2026 5:41 PM - SEC Filing Form 4 NEUROCRINE BIOSCIENCES For: Jun 05 Filed by: Onyia Jude June 9, 2026 5:35 PM - SEC Filing Form 4 NEUROCRINE BIOSCIENCES For: Jun 04 Filed by: Norwalk Leslie V June 8, 2026 6:08 PM - SEC Filing Neurocrine presents tardive dyskinesia treatment data at conference June 8, 2026 4:05 PM - StreetInsider Neurocrine Biosciences Presents New Clinically Meaningful Response Data on Treatment of Tardive Dyskinesia, Reinforcing the Efficacy of INGREZZA® (valbenazine) Capsules Across a Broad Range of Patien June 8, 2026 4:05 PM - PR NewsWire Neurocrine presents INGREZZA data for tardive dyskinesia patients June 8, 2026 8:31 AM - StreetInsider Neurocrine Biosciences Presents New Data Highlighting Functional and Socio-emotional Improvements with INGREZZA® (valbenazine) Capsules in Individuals with Tardive Dyskinesia and Intellectual and Dev June 8, 2026 8:30 AM - PR NewsWire Form 144 NEUROCRINE BIOSCIENCES Filed by: SHERWIN STEPHEN A June 5, 2026 4:32 PM - SEC Filing Morgan Stanley tracks prescription trends for US neurology drugs June 5, 2026 8:59 AM - StreetInsider Form 4 NEUROCRINE BIOSCIENCES For: Jun 02 Filed by: Cooke Julie June 4, 2026 6:03 PM - SEC Filing Form 4 NEUROCRINE BIOSCIENCES For: Jun 02 Filed by: Keswani Sanjay Chandru June 4, 2026 5:54 PM - SEC Filing Neurocrine to present two-year CRENESSITY data at medical meeting June 3, 2026 8:31 AM - StreetInsider Neurocrine Biosciences to Present New Two‑Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient‑Reported Outcome Measures at ENDO 2026 June 3, 2026 8:30 AM - PR NewsWire Form 4 NEUROCRINE BIOSCIENCES For: Jun 01 Filed by: Onyia Jude June 2, 2026 6:08 PM - SEC Filing Form 4 NEUROCRINE BIOSCIENCES For: May 29 Filed by: Delaet Ingrid June 2, 2026 6:03 PM - SEC Filing Form 144 NEUROCRINE BIOSCIENCES Filed by: Cooke Julie June 2, 2026 4:39 PM - SEC Filing Goldman Sachs Resumes Neurocrine Bio. (NBIX) at Buy June 2, 2026 5:07 AM - StreetInsider Form 144 NEUROCRINE BIOSCIENCES Filed by: Onyia Jude June 1, 2026 4:25 PM - SEC Filing Form 4 NEUROCRINE BIOSCIENCES For: May 27 Filed by: Onyia Jude May 29, 2026 6:10 PM - SEC Filing Form 4 NEUROCRINE BIOSCIENCES For: May 27 Filed by: GORMAN KEVIN CHARLES May 29, 2026 6:06 PM - SEC Filing Form 4 NEUROCRINE BIOSCIENCES For: May 27 Filed by: POPS RICHARD F May 29, 2026 6:05 PM - SEC Filing Form 4 NEUROCRINE BIOSCIENCES For: May 27 Filed by: LYONS GARY A May 29, 2026 6:05 PM - SEC Filing Form 4 NEUROCRINE BIOSCIENCES For: May 27 Filed by: Mercier Johanna May 29, 2026 6:04 PM - SEC Filing Form 4 NEUROCRINE BIOSCIENCES For: May 27 Filed by: POON CHRISTINE A May 29, 2026 6:04 PM - SEC Filing Form 4 NEUROCRINE BIOSCIENCES For: May 27 Filed by: Sharp Shalini May 29, 2026 6:03 PM - SEC Filing Form 4 NEUROCRINE BIOSCIENCES For: May 27 Filed by: SHERWIN STEPHEN A May 29, 2026 6:03 PM - SEC Filing Form 4 NEUROCRINE BIOSCIENCES For: May 27 Filed by: MORROW GEORGE J May 29, 2026 6:02 PM - SEC Filing Form 4 NEUROCRINE BIOSCIENCES For: May 27 Filed by: RASTETTER WILLIAM H May 29, 2026 6:02 PM - SEC Filing Form 4 NEUROCRINE BIOSCIENCES For: May 27 Filed by: Norwalk Leslie V May 29, 2026 6:01 PM - SEC Filing Form 144 NEUROCRINE BIOSCIENCES Filed by: Delaet Ingrid May 29, 2026 4:25 PM - SEC Filing Form 4 NEUROCRINE BIOSCIENCES For: May 26 Filed by: Boyer David W. May 28, 2026 6:09 PM - SEC Filing Form 8-K NEUROCRINE BIOSCIENCES For: May 27 May 28, 2026 4:45 PM - SEC Filing Form 144 NEUROCRINE BIOSCIENCES Filed by: Onyia Jude May 27, 2026 4:34 PM - SEC Filing Form 144 NEUROCRINE BIOSCIENCES Filed by: Boyer David W. May 26, 2026 4:45 PM - SEC Filing Neurocrine Biosciences to Present at Upcoming Investor Conferences in June May 26, 2026 4:01 PM - PR NewsWire Form 4 NEUROCRINE BIOSCIENCES For: May 21 Filed by: SHERWIN STEPHEN A May 21, 2026 7:25 PM - SEC Filing Form 4 NEUROCRINE BIOSCIENCES For: May 21 Filed by: Sharp Shalini May 21, 2026 7:24 PM - SEC Filing Form 4 NEUROCRINE BIOSCIENCES For: May 21 Filed by: RASTETTER WILLIAM H May 21, 2026 7:24 PM - SEC Filing Form 4 NEUROCRINE BIOSCIENCES For: May 21 Filed by: POPS RICHARD F May 21, 2026 7:23 PM - SEC Filing Form 4 NEUROCRINE BIOSCIENCES For: May 21 Filed by: POON CHRISTINE A May 21, 2026 7:23 PM - SEC Filing Form 4 NEUROCRINE BIOSCIENCES For: May 21 Filed by: Norwalk Leslie V May 21, 2026 7:22 PM - SEC Filing Form 4 NEUROCRINE BIOSCIENCES For: May 21 Filed by: MORROW GEORGE J May 21, 2026 7:22 PM - SEC Filing Form 4 NEUROCRINE BIOSCIENCES For: May 21 Filed by: Mercier Johanna May 21, 2026 7:21 PM - SEC Filing Form 4 NEUROCRINE BIOSCIENCES For: May 21 Filed by: LYONS GARY A May 21, 2026 7:21 PM - SEC Filing Form 4 NEUROCRINE BIOSCIENCES For: May 19 Filed by: GORMAN KEVIN CHARLES May 21, 2026 5:50 PM - SEC Filing Bernstein SocGen Group Starts Neurocrine Bio. (NBIX) at Outperform May 21, 2026 4:23 PM - StreetInsider Form 144 NEUROCRINE BIOSCIENCES Filed by: GORMAN KEVIN CHARLES May 19, 2026 4:31 PM - SEC Filing Form 4 NEUROCRINE BIOSCIENCES For: May 15 Filed by: POPS RICHARD F May 18, 2026 5:51 PM - SEC Filing Neurocrine presents data on INGREZZA treatment for mild tardive dyskinesia May 18, 2026 4:06 PM - StreetInsider Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules May 18, 2026 4:05 PM - PR NewsWire Form 8-K NEUROCRINE BIOSCIENCES For: May 14 May 18, 2026 9:05 AM - SEC Filing Neurocrine completes $2.9 billion acquisition of Soleno Therapeutics May 18, 2026 8:47 AM - StreetInsider Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics May 18, 2026 8:47 AM - PR NewsWire Form 144 NEUROCRINE BIOSCIENCES Filed by: POPS RICHARD F May 15, 2026 4:39 PM - SEC Filing Form 4 NEUROCRINE BIOSCIENCES For: May 12 Filed by: Norwalk Leslie V May 14, 2026 4:45 PM - SEC Filing 4basebio appoints Richard Bungay as CFO, announces board changes May 14, 2026 7:00 AM - StreetInsider Form 144 NEUROCRINE BIOSCIENCES Filed by: Norwalk Leslie V May 12, 2026 2:36 PM - SEC Filing Neurocrine Bio. (NBIX) PT Raised to $155 at Truist Securities May 6, 2026 1:16 PM - StreetInsider Neurocrine publishes expert guidelines for glucocorticoid reduction with CRENESSITY May 6, 2026 8:32 AM - StreetInsider Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hy May 6, 2026 8:30 AM - PR NewsWire Neurocrine Bio. (NBIX) PT Raised to $191 at Morgan Stanley May 6, 2026 8:14 AM - StreetInsider Neurocrine Bio. (NBIX) PT Raised to $144 at BMO Capital May 6, 2026 8:03 AM - StreetInsider Neurocrine Bio. (NBIX) PT Raised to $207 at Piper Sandler May 6, 2026 7:15 AM - StreetInsider Neurocrine Bio. (NBIX) PT Raised to $180 at RBC Capital May 6, 2026 6:40 AM - StreetInsider Neurocrine Bio. (NBIX) PT Raised to $176 at Wedbush May 6, 2026 6:33 AM - StreetInsider Neurocrine Bio. (NBIX) PT Raised to $230 at Oppenheimer May 6, 2026 6:11 AM - StreetInsider Neurocrine Biosciences (NBIX) Tops Q1 EPS by 77c, Beats on Revenue May 5, 2026 4:14 PM - StreetInsider Form 10-Q NEUROCRINE BIOSCIENCES For: Mar 31 May 5, 2026 4:04 PM - SEC Filing Form 8-K NEUROCRINE BIOSCIENCES For: May 05 May 5, 2026 4:02 PM - SEC Filing Neurocrine Biosciences Reports First-Quarter 2026 Financial Results May 5, 2026 4:01 PM - PR NewsWire Neurocrine Biosciences to Present at the Bank of America Health Care Conference 2026 May 5, 2026 9:00 AM - PR NewsWire Neurocrine Biosciences Announces New Survey Results Showing Significant Burden of Tardive Dyskinesia on Employment May 4, 2026 8:30 AM - PR NewsWire Neurocrine begins phase 1 trial of obesity drug targeting new mechanism May 4, 2026 7:30 AM - StreetInsider Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'2118, a Corticotropin-Releasing Factor Type 2 Receptor Agonist May 4, 2026 7:30 AM - PR NewsWire Neurocrine shows sustained pediatric results for CRENESSITY in two-year study May 1, 2026 4:06 PM - StreetInsider Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Durable Hormone Control, Reduced Glucocorticoid Exposure and Meaningful Clinical Improvements in Pediatric P May 1, 2026 4:05 PM - PR NewsWire Form SCHEDULE 13G NEUROCRINE BIOSCIENCES Filed by: VANGUARD CAPITAL MANAGEMENT LLC April 30, 2026 11:41 AM - SEC Filing Neurocrine publishes tardive dyskinesia scale validation research April 29, 2026 4:07 PM - StreetInsider Neurocrine Biosciences Announces Publication Establishing Clinically Meaningful Improvement Threshold for the Tardive Dyskinesia Impact Scale April 29, 2026 4:05 PM - PR NewsWire Full Article List